达唯珂折戟,创新药研发安全红线再敲警钟

21世纪经济报道
Mar 10

21世纪经济报道记者 闫硕在国内获批仅一年,和黄医药代理的肿瘤药品达唯珂(他泽司他)便宣告撤市,引发市场广泛关注。3月9日晚间,和黄医药发布公告称,已在中国内地、香港及澳门启动达唯珂撤市及产品召回程序,并同步停止所有正在进行的他泽司他的临床试验。此次调整源于,原研企业益普生通知将在美国自愿撤市该药品,并同步停止相关临床试验,和黄医药随即响应。与此同时,国家医保局发布公告,自2026年3月9日起,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10